Boeing (BA) Tops Q3 EPS by 30c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Boeing (BA) Reports 3Q EPS Beat; Canaccord Genuity Reiterates Buy
October 22, 2015 10:27 AM EDTCanaccord Genuity reiterated a Buy rating and $165.00 price target on Boeing (NYSE: BA) following the company's 3Q15 earnings results. BA reported adjusted core EPS of $2.52 compared to the consensus estimates of $2.22.
Analyst Ken Herbert commented, "Boeing reported a better than expected Q3/15... More
RBC Capital Raises Price Target on Boeing (BA) Following 3Q15 EPS Beat
October 21, 2015 3:19 PM EDTRBC Capital reiterated a Sector Perform rating on Boeing (NYSE: BA), and raised the price target to $149.00 (from $145.00) following the company's 3Q15 earnings results. BA reported 'core' EPS of $2.52 coming in ahead of consensus at $2.21. Boeing defined 'core' EPS guidance was increased from... More
Wall St. declines; Valeant, healthcare weigh
October 21, 2015 7:08 AM EDTBy Caroline Valetkevitch
(Reuters) - U.S. stocks fell on Wednesday as a sharp drop in Valeant Pharmaceuticals hit the healthcare space, while the energy sector dropped along with oil prices.
Valeant Pharmaceuticals' (NYSE: VRX) U.S.-listed shares plunged to an intraday low of $88.50 on record volume after a short-seller accused the company of using specialty pharmacies to inflate its revenue.
The company denied the allegation, and later investor Bill Ackman said he increased his Valeant stake by about 2 million shares. The stock pared losses to end down 19.2 percent at $118.61,... More
